Adjuvant Ipilimumab effects survival after high risk lymph node and melanoma resection

20 abril 2015

Adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, research indicates, but that this treatment was also associated with a high rate of immune-related adverse events.